Sort
25,944 grants matching “neurodegeneration”
La Jolla-Parkinson's Disease Center Grant
$1,603,108Stuart A Lipton · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2009 · ES
A system approach to targeting innate immunity in AD
$1,602,041Todd E. Golde · University Of Florida · U01 · FY2013 · AG
Brain pathologies, reserve and cognition in aging and dementia
$1,601,935Sarah E Tomaszewski-Farias · University Of California At Davis · R01 · FY2023 · AG
Gene Therapy for Batten Disease
$1,601,406Ronald G Crystal · Weill Medical Coll Of Cornell Univ · U01 · FY2008 · NS
Gene Therapy for Batten Disease
$1,601,368Ronald G Crystal · Weill Medical Coll Of Cornell Univ · U01 · FY2007 · NS
PARKINSON'S DISEASE RESEARCH CENTER AT COLUMBIA
$1,601,258Columbia University Health Sciences · P50 · FY2001 · NS
Sexual dimorphic cell type and connectivity atlases of the aging and AD mouse brains
$1,600,950Hong-Wei Dong · University Of California Los Angeles · R01 · FY2024 · AG
Novel Histone Deacetylase Inhibitors as Therapeutics for Huntington's Disease
$1,600,018Joel M. Gottesfeld · Scripps Research Institute, The · U01 · FY2012 · NS
"THE ROLE OF PP2A METHYLATION IN SUSCEPTIBILITY AND RESISTANCE TO TBI AND AD-INDUCED NEURODEGENERATION"
$1,600,000The Trustees Of Columbia University In The City Of New York · · FY2012 · Department of Defense
Achieving specificity in imaging neurodegeneration with visible light Optical Coherence Tomography
$1,599,999Vivek Jay Srinivasan · New York University School Of Medicine · OT2 · FY2024 · OD
Discovery of novel TDP-43 splicing targets: the Achilles heel for FTD and towards sensitive biomarkers and therapeutic targets
$1,598,861Aaron D. Gitler · Stanford University · U54 · FY2024 · NS
Discovery of novel TDP-43 splicing targets: the Achilles heel for FTD and towards sensitive biomarkers and therapeutic targets
$1,597,452Aaron D. Gitler · Stanford University · U54 · FY2023 · NS
A system approach to targeting innate immunity in AD
$1,597,190Todd E. Golde · University Of Florida · U01 · FY2015 · AG
Development of PU.1 Inhibitory Modulators as Novel Therapeutics for Alzheimer's Disease
$1,595,511Li-Huei Tsai · Massachusetts Institute Of Technology · U01 · FY2021 · AG
A Phase 3 Pivotal Trial of AGB101 to Slow Progression in MCI due to Alzheimer's Disease
$1,595,216Richard C. Mohs · Agenebio, Inc. · R01 · FY2022 · AG
Functional Genomic Dissection of Alzheimer's Disease in Humans and Drosophila Models
$1,594,999Joshua M Shulman · Baylor College Of Medicine · U01 · FY2023 · AG
Preclinical Development of JNK3 Inhibitors to Treat Parkinson's Disease
$1,594,607Philip Lograsso · Scripps Research Institute, The · U01 · FY2012 · NS
Preclinial Development of JNK3 Inhibitors to Treat Parkinson's Disease
$1,594,607Philip Lograsso · Scripps Research Institute, The · U01 · FY2012 · NS
Synaptic Vesicle Endocytosis
$1,593,502Ling Gang Wu · National Institute Of Neurological Disorders And Stroke · ZIA · FY2016 · NS
Functional Genetics of Susceptibility to Prions
$1,593,334Mc Laughlin Research Institute · P01 · FY2001 · NS
Cellular mechanisms of neuronal dysfunction in addiction and neurodegeneration
$1,593,318Brandon Harvey · National Institute On Drug Abuse · ZIA · FY2021 · DA
A system approach to targeting innate immunity in AD
$1,592,165Todd E. Golde · University Of Florida · U01 · FY2016 · AG
Functional Genomic Dissection of Alzheimer's Disease in Humans and Drosophila Models
$1,589,683Joshua M Shulman · Baylor College Of Medicine · U01 · FY2024 · AG
Novel Histone Deacetylase Inhibitors as Therapeutics for Huntington's Disease
$1,588,726Joel M. Gottesfeld · Scripps Research Institute, The · U01 · FY2011 · NS
NEURONAL &VASCULAR PATHOBIOLOGY IN ALZHEIMER'S DISEASE
$1,588,410Nathan S. Kline Institute For Psych Res · P01 · FY2002 · AG